补肺解毒汤对气阴两虚型肺癌患者化疗的增效减毒作用

Clinical Research on Treatment of Qiyinliangxu-type Lung Cancer Based on Bufei Jiedu Soup Combined with Chemotherapy

目的:观察补肺解毒汤加减联合化疗治疗中晚期气阴两虚型非小细胞肺癌患者的临床疗效。方法:将70例中晚期气阴两虚型非小细胞肺癌患者按照随机数字表法分为治疗组35例和对照组35例,对照组采用化疗治疗,治疗组在对照组治疗的基础上加用补肺解毒汤治疗,治疗4个周期后,观察两组临床疗效,Karnofsky功能状态评分标准(KPS)评分、骨髓抑制情况、免疫功能改善、毒副反应情况。结果:补肺解毒汤联合化疗组和化疗组总有效率分别为85.72%,62.86%,补肺解毒汤联合化疗组近期疗效明显优于化疗组,呈显著性差异(P<0.05);补肺解毒汤联合化疗组和化疗组患者生活质量提高率分别为62%,33.33%,补肺解毒汤联合化疗组明显优于化疗组,呈显著性差异(P<0.05);补肺解毒汤联合化疗组出现外周血象异常情况明显低于化疗组,具有显著性差异(P<0.05);补肺解毒汤联合化疗组和化疗组治疗前后比较,CD4+,CD8+,CD4+/CD8+和自然杀伤(NK)细胞活性等免疫指标均呈现不同程度的显著性差异(P<0.05),补肺解毒汤联合化疗组比化疗组免疫力明显提高;与化疗组比较,补肺解毒汤联合化疗组不良反应发生率明显低于对照组,呈显著性差异(P<0.05)。结论:补肺解毒汤为基础方加减联合化疗药物治疗气阴两虚型中晚期非小细胞肺癌能有效缓解患者临床症状,减轻患者化疗的毒副反应,提高机体免疫力,改善生活质量等方面起协同作用,在临床可以广泛应用。

Objective： The purpose of this paper was to investigate the clinical efficacy of treatment on the Qiyinliangxu-type lung cancer by chemotherapy with or without Bufei Jiedu soup. Method： Seventy cases of Qiyinliangxu-type lung cancer in middle and late period were randomly grouped into chemotherapy group and Bufei Jiedu soup combined with chemotherapy group, with 35 cases in each group. The chemotherapy groups were only treated by western medicine chemotherapy scheme, while the Bufei Jiedu soup combined with chemotherapy groups were cured with Bufei Jiedu soup based on the treatment of control group. After 4 continuous treatment periods, the short-term curative effect, improvement of life quality, improvement of peripheral blood and immune function, and the occurrence of adverse reaction were examined. Result： The total effective rates in chemotherapy group and Bufei Jiedu soup combined with chemotherapy group were 85.72% and 62.86% , respectively. The short-term curative effect in Bufei Jiedu soup combined with chemotherapy group was significantly better than the chemotherapy group （P 〈 0.05 ） ; as to the improvement of life quality, the Bufei Jiedu soup combined with chemotherapy group was significantly better than the chemotherapy group （P 〈 0.05） with the improvement rate of life quality of 62.00% and 33.33% , respectively. The peripheral blood abnormality rates in Bufei Jiedu soup combined with chemotherapy group were significantly lower than the chemotherapy group （P 〈 0.05） ; the immune indexes （CD4 ＋ , CD8 ＋ , CD4 ＋/CD8 ＋ and the activity of NK cell） were compared before and after treatment in both Bufei Jiedu soup combined with chemotherapy group and chemotherapy group, and all showed significant difference in different degree （P 〈 O. 05） , so the immunity of Bufei Jiedu soup combined with chemotherapy group was obviously improved. Compared with chemotherapy group, the occurrence rate of adverse reaction in Bufei Jiedu soup combined with chemotherapy group was significantly lower than chemotherapy group （P 〈0.05）. Conclusion： In the case of Qiyinliangxu-type lung cancer, the treatment of chemotherapy with or without Bufei Jiedu soup could effectively relieve the clinical symptoms, improve the immunity, reduce the occurrence of adverse reaction, and improve the life quality, and the TCM treatment combined with chemotherapy had the efficacy improved and toxicity lowered, and it was worthy of promotion and application in clinico